Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

• Status: Terminated
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited

Criteria

Inclusion Criteria:

• Aged between 20 and 64 years(Both genders)

• more than 2 among components of the metabolic syndrome

• Triglyceride >= 150mg/dL

• HDL-D: Women < 50mg/dL or Men < 40mg/dL

• Hypertension: Systolic blood pressure >= 130mmHg or Diastolic blood pressure >= 85mmHg

• Hyperglycemia: fasting plasma glucose >= 100 mg/dL

• Informed consent awarding

Exclusion Criteria:

• Alcohol or any drug abuse

• Any investigational medication during the preceding 3 months